# OnCo record nct02362594 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02362594/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02362594", "NCT02362594" ;
  schema:name "Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)"@en ;
  schema:alternateName "KEYNOTE-054"@en ;
  schema:description "A phase 3 trial of Pembrolizumab in melanoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02362594/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02362594> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2015-07-16" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/stage-iii-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-054-eggermont-nejm-2018/>, <https://onco.cc/key-papers/paper-nct02362594-lancet-oncol-2021-update/> .